Search Patents
-
Patent number: 6239101Abstract: Small, buffer soluble polypeptides having amino acid structures corresponding to residues 234-486, 310-486, and 407-486, of thrombomodulin and functionally equivalent analogs thereof inhibiting the clotting activity of thrombin and increasing protein C activation. The polypeptides can be coated onto the surface of articles adapted for contacting mammalian blood to render the surface non-thrombogenic. In pharmaceutical compositions, the polypeptides act as a natural anticoagulant.Type: GrantFiled: January 31, 1991Date of Patent: May 29, 2001Assignee: Oklahoma Medical Research FoundationInventors: Charles T. Esmon, Naomi L. Esmon, Deborah J. Stearns, Shinichiro Kurosawa
-
Patent number: 5239056Abstract: A peptide fraction inducing the formation of antibodies which protect against the bovine leukemia virus (BLV), wherein it includes a peptide sequence which reproduces all or part of the sequence of the glycoprotein envelope gp51 fragment of the BLV virus which bears at least one of the epitopes (F, G, H) responsible for the biological activity of the virus. This fraction may be the fragment itself or a synthetic peptide. Application is made to the preparation or search for antibodies, to diagnosis and to the preparation of vaccines.Type: GrantFiled: February 5, 1992Date of Patent: August 24, 1993Assignee: Rhone MerieuxInventors: Daniel G. J. G. Portetellie, Arsene Leon G. Burny, Corine F. Dandoy, Helene S. C. Gras, nee Masse, Andre L. Tartar
-
Patent number: 5434245Abstract: There is provided a polypeptide having the following formula (I'), and which polypeptide is referred to as Glu-OC and a process for the preparation thereof.Type: GrantFiled: December 16, 1992Date of Patent: July 18, 1995Assignee: Takara Shuzo Co., Ltd.Inventors: Nobuto Koyama, Fusao Kimizuka, Ikunoshin Kato
-
Patent number: 5464823Abstract: Peptide-based compounds containing four invariant cysteine residues which have been oxidized to obtain two intramolecular disulfide bonds are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants. These compounds, in one embodiment, are of the formula:A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -C-A.sub.7 -C-A.sub.9 -A.sub.10 -A.sub.11 -A.sub.12 -C-A.sub.14 -C-A.sub.16 -(A.sub.17 -A.sub.18)(1) (SEQ ID NO:4)and the N-terminal acylated, C-terminal amidated or esterified and the cystine-bridged forms thereofwherein A.sub.1, A.sub.9, A.sub.10 and A.sub.11 are basic amino acids;A.sub.2 and A.sub.3 are small amino acids;A.sub.5, A.sub.7, A.sub.12, A.sub.14 and A.sub.16 are hydrophobic amino acids; andA.sub.4 is a basic or a small amino acid;A.sub.17 is not present or, if present, is a small amino acid;A.sub.18 is not present or, if present, is a basic amino acid.Type: GrantFiled: July 26, 1993Date of Patent: November 7, 1995Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Vladimir N. Kokryakov, Sylvia S. L. Harwig
-
Patent number: 5032573Abstract: Microbially produced aprotinin and aprotinin homologs used for treating patients suffering from an excess release of pancreatic elastase, serum elastase or leukocyte elastase.Type: GrantFiled: October 2, 1989Date of Patent: July 16, 1991Assignee: Bayer AktiengesellschaftInventors: Ernst-August Auerswald, Werner Schroder, Eugen Schnabel, Wolfgang Bruns, Gerd Reinhardt, Michael Kotick
-
Patent number: 5095092Abstract: The invention relates to a process for the isolation and purification of hirudin from complex and salt-containing solutions by hydrophobic chromatography, using as stationary phase porous adsorber resins and as mobile phase organic solvents which are miscible with water.Type: GrantFiled: September 27, 1990Date of Patent: March 10, 1992Assignee: Hoechst AktiengesellschaftInventors: Werner Badziong, Peter Crause, Paul Habermann, Dominique Tripier
-
Patent number: 5326580Abstract: Disclosed herein is a protein sweetener that has been isolated from Pentadiplandra brazzeana Baillon. The sweetener is thermostable, lysine rich, and has a relative long lasting taste. Also disclosed is a recombinant host capable of producing the sweetener in large quantities. Compositions of this sweetener with other sweeteners are also disclosed.Type: GrantFiled: February 16, 1993Date of Patent: July 5, 1994Assignee: Wisconsin Alumni Research FoundationInventors: Bengt G. Hellekant, Ding Ming
-
Patent number: 5478923Abstract: Single-chain analogs of the naturally occurring two-chain peptide monellin retain the sweetening properties of the natural protein and are stable under conditions which would otherwise destabilize the native peptide. A covalent linkage joins peptides corresponding to portions of the A and B chains of the naturally occurring protein.Type: GrantFiled: March 25, 1994Date of Patent: December 26, 1995Assignees: The Regents of the University of California, Lucky, Ltd.Inventors: Sung-Hou Kim, Joong M. Cho
-
Patent number: 5268358Abstract: Methods and compositions are provided for treating several acute disease states associated with smooth muscle cell proliferation as well as the chronic process of atherogenesis utilizing oligopeptides corresponding to regions of the PDGF receptor protein. The oligopeptides can be used to block PDGF binding and activation for numerous applications, and can serve as immunogens to raise receptor-specific antibodies.Type: GrantFiled: May 6, 1991Date of Patent: December 7, 1993Assignee: Cor Therapeutics, Inc.Inventor: Larry J. Fretto
-
Patent number: 5846733Abstract: The phosphorylated structural protein of molecular weight about 150 kd (pp 150) of human cytomegalovirus (HCMV) is highly immunogenic and is reliably recognised by human antisera. This protein can, after assignment and sequencing of the gene, be prepared, in whole or in immunogenic sections, by gene manipulation. Proteins of this type are suitable as reagents, for example in an ELISA, and as constituents of vaccines.Type: GrantFiled: April 28, 1995Date of Patent: December 8, 1998Assignee: Behring Diagnositcs GmbHInventors: Gerhard Jahn, Birgit-Christine Scholl, Michael Broker, Michael Mach, Bernhard Fleckenstein, Bernd Traupe
-
Patent number: 5482928Abstract: Biocidal proteins isolated from Mirabilis have been characterized. The proteins show a wide range of antifungal activity and are active against gram-positive bacteria. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA have been produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.Type: GrantFiled: December 20, 1993Date of Patent: January 9, 1996Assignee: Imperial Chemical Industries PLCInventors: Miguel De Bolle, Willem F. Broekaert, Bruno P. A. Cammue, Sarah B. Rees, Jozef Vanderleyden
-
Patent number: 5118668Abstract: Peptides having essentially the sequence of bovine pancreatic trypsin inhibitor (aprotinin) wherein one or more of the amino acids at positions 15, 16, 17, 18, 34, 39 and 52 are replaced by any naturally occurring amino acid produced by recombinant DNA technology, process, expression vector and recominant host therefor and pharmaceutical use thereof. Such peptides being useful as therapeutic agents in diseases connected with the presence of excessive amounts of proteinases.Type: GrantFiled: July 20, 1988Date of Patent: June 2, 1992Assignee: Bayer AktiengesellschaftInventors: Ernst-August Auerswald, Wolfgang Bruns, Dietrich Horlein, Gerd Reinhardt, Eugen Schnabel, Werner Schroder
-
Patent number: 5422427Abstract: The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.Type: GrantFiled: September 17, 1991Date of Patent: June 6, 1995Assignee: The United States of America as represented by the United States Department of Health and Human ServicesInventors: Harold Russell, Jacquelyn Sampson, Steven P. O'Connor
-
Patent number: 5432155Abstract: Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetylcholine receptor, and ion channels. The peptides are of such length that they can be made by chemical synthesis. They also may be made using recombinant DNA techniques, and the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest.Type: GrantFiled: June 29, 1993Date of Patent: July 11, 1995Assignees: The Salk Institute For Biological Studies, University of Utah Research FoundationInventors: Baldomero M. Olivera, Jean E. F. Rivier, Lourdes J. Cruz, Fe Abogadie, Chris E. Hopkins, John Dykert, Josep L. Torres